Market Closed -
OTC Markets
17:32:14 13/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.875
USD
|
+9.38%
|
|
+53.51%
|
+191.67%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Capitalization
1 |
49.28
|
11.38
|
35.95
|
Enterprise Value (EV)
1 |
51.94
|
12.16
|
36.33
|
P/E ratio
|
-31.9
x
|
-9.36
x
|
-30.1
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
39,599,158
x
|
109,154,656
x
|
59,447,104
x
|
EV / Revenue
|
41,741,978
x
|
116,560,264
x
|
60,084,725
x
|
EV / EBITDA
|
-34.1
x
|
-10.3
x
|
-36.2
x
|
EV / FCF
|
-54,689,651
x
|
-33,076,781
x
|
80,445,030
x
|
FCF Yield
|
-0%
|
-0%
|
0%
|
Price to Book
|
-376
x
|
-20.1
x
|
-19.5
x
|
Nbr of stocks (in thousands)
|
118,182
|
119,821
|
119,821
|
Reference price
2 |
0.4170
|
0.0950
|
0.3000
|
Announcement Date
|
15/04/22
|
14/04/23
|
12/04/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
1.354
|
1.244
|
0.1043
|
0.6047
|
EBITDA
1 |
-0.231
|
-0.6987
|
-1.521
|
-1.178
|
-1.005
|
EBIT
1 |
-0.2311
|
-0.7118
|
-1.543
|
-1.205
|
-1.195
|
Operating Margin
|
-
|
-52.58%
|
-123.99%
|
-1,155.72%
|
-197.58%
|
Earnings before Tax (EBT)
1 |
-0.2312
|
-0.7118
|
-1.542
|
-1.205
|
-1.195
|
Net income
1 |
-0.2312
|
-0.7118
|
-1.542
|
-1.205
|
-1.195
|
Net margin
|
-
|
-52.58%
|
-123.95%
|
-1,155.5%
|
-197.64%
|
EPS
2 |
-0.0231
|
-0.0708
|
-0.0131
|
-0.0101
|
-0.009973
|
Free Cash Flow
|
-
|
0.274
|
-0.9498
|
-0.3675
|
0.4516
|
FCF margin
|
-
|
20.24%
|
-76.33%
|
-352.39%
|
74.69%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/01/21
|
19/04/21
|
15/04/22
|
14/04/23
|
12/04/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.55
|
-
|
2.67
|
0.77
|
0.39
|
Net Cash position
1 |
-
|
1.07
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-2.36
x
|
-
|
-1.753
x
|
-0.6558
x
|
-0.3838
x
|
Free Cash Flow
|
-
|
0.27
|
-0.95
|
-0.37
|
0.45
|
ROE (net income / shareholders' equity)
|
-
|
-85.9%
|
-298%
|
346%
|
99.2%
|
ROA (Net income/ Total Assets)
|
-
|
-24.9%
|
-27.4%
|
-21.7%
|
-37.2%
|
Assets
1 |
-
|
2.859
|
5.624
|
5.548
|
3.214
|
Book Value Per Share
2 |
0.0500
|
0.1200
|
-0
|
-0
|
-0.0200
|
Cash Flow per Share
2 |
0
|
0.1400
|
0
|
0
|
0
|
Capex
1 |
0.04
|
0.04
|
0.56
|
-
|
-
|
Capex / Sales
|
-
|
3.14%
|
45.38%
|
-
|
-
|
Announcement Date
|
14/01/21
|
19/04/21
|
15/04/22
|
14/04/23
|
12/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +191.67% | 105M | | +26.37% | 48.16B | | -1.01% | 41.73B | | +41.48% | 41.03B | | -5.31% | 28.77B | | +9.34% | 25.59B | | -21.69% | 18.96B | | +6.23% | 12.92B | | +26.99% | 12.03B | | -3.38% | 11.77B |
Other Biotechnology & Medical Research
|